In the hormone sensitive LNCaP prostate cancer cell line model, upregulation of BCL-2 is required for progression from an androgen-dependent to androgen-independent state, and overexpression of BCL-2 confers resistance to androgen depletion, protecting cells against apoptosis [49,51,192]. This evidence concerns the gene BCL2 and prostate carcinoma.